Diabetic Ketoacidosis Associated with Sodium‐Glucose Cotransporter 2 Inhibitors: Clinical and Biochemical Characteristics of 29 Cases
Stamatiades G, D’Silva P, Elahee M, Viana G, Sideri-Gugger A, Majumdar S. Diabetic Ketoacidosis Associated with Sodium‐Glucose Cotransporter 2 Inhibitors: Clinical and Biochemical Characteristics of 29 Cases. International Journal Of Endocrinology 2023, 2023: 6615624. PMID: 37441367, PMCID: PMC10335870, DOI: 10.1155/2023/6615624.Peer-Reviewed Original ResearchCommon presenting symptomAbdominal painEuglycemic DKAPresenting symptomSodium-glucose cotransporter 2 inhibitorsType 2 diabetes mellitusAverage blood glucose concentrationCases of DKAPoor food intakePoor oral intakeCotransporter 2 inhibitorsRetrospective case seriesSGLT2 inhibitor useDiabetic Ketoacidosis AssociatedPotential risk factorsBlood glucose concentrationVariety of drugsAnion gap valuesSGLT2i useDiabetes durationDiabetes mellitusDKA casesInhibitor useOral intakeCase series
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply